06.06.2023 07:00:07 - dpa-AFX: GNW-Adhoc: AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals

LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences,
Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving
outcomes for patients with cancer, today announced the establishment of a joint
clinical collaboration agreement with University Hospitals.
Per the terms of this agreement, University Hospitals will provide tissue
samples with clinical outcomes to AccuStem for research purposes. The scope of
the agreement covers a multitude of different cancers but will initially focus
on breast cancer cases to support further validation of the StemPrintER test.
The goal of the initial project is to build on the strong foundation of data for
StemPrintER by demonstrating additional clinical utility beyond identifying
patients' risk of recurrence. This next step is critical for women with early
stage breast cancer because there are many tests to determine the need for
chemotherapy but there are no genomic tools to inform decisions earlier in the
continuum of care. StemPrintER may be able to shift this paradigm by informing
physicians of the most effective approaches to surgical or radiological
treatment.
"AccuStem has arrived at an important juncture as we progress toward
commercializing StemPrintER," said Wendy Blosser, Chief Executive Officer of
AccuStem. "With this collaboration, we intend to expand beyond identifying a
patient's prognosis by addressing unanswered clinical questions and supporting
surgeons and radiation oncologists with their treatment planning."
AccuStem and its clinical collaborators plan to present the data obtained under
this agreement at scientific conferences and to publish the findings in peer-
reviewed medical journals. Those activities will help to bolster the foundation
of data for StemPrintER and familiarize physicians with its utility and value in
clinical decision making with the ultimate goal of improving patient outcomes
and quality of life.
"We are excited to work with AccuStem on this clinical project," said Hannah
Gilmore, Division Chief, Anatomic Pathology, University Hospitals Cleveland
Medical Center and Professor of Pathology, Case Western Reserve University. "I
am very interested in the foundation for the StemPrintER test and think that it
could have important implications for treatment planning in breast cancer and
perhaps many other tumor types."
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing
outcomes and quality of life for all patients with cancer. We plan to drive
innovation in healthcare by offering proprietary molecular testing that
addresses unmet clinical needs from cancer screening through treatment and
monitoring. By interrogating novel disease pathways, such as tumor "stemness",
we believe our tools will help care teams better understand the biology of each
patient's cancer, leading to more informed decision making. For more
information, please visit www.accustem.com (https://accustem.com/).
About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an
integrated network of 21 hospitals (including five joint ventures), more than
50 health centers and outpatient facilities, and over 200 physician offices in
16 counties throughout northern Ohio. The system's flagship quaternary care,
academic medical center, University Hospitals Cleveland Medical Center, is
affiliated with Case Western Reserve University School of Medicine, Northeast
Ohio Medical University, Oxford University, the Technion Israel Institute of
Technology and National Taiwan University College of Medicine. The main campus
also includes the UH Rainbow Babies & Children's Hospital, ranked among the top
children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only
hospital for women; and UH Seidman Cancer Center, part of the NCI-designated
Case Comprehensive Cancer Center. UH is home to some of the most prestigious
clinical and research programs in the nation, with more than 3,000 active
clinical trials and research studies underway. UH Cleveland Medical Center is
perennially among the highest performers in national ranking surveys, including
"America's Best Hospitals" from U.S. News & World Report. UH is also home to 19
Clinical Care Delivery and Research Institutes. UH is one of the largest
employers in Northeast Ohio with more than 30,000 employees. Follow UH on
LinkedIn (https://www.linkedin.com/company/university-
hospitals/?viewAsMember=true), Facebook
(https://www.facebook.com/UniversityHospitals/) and Twitter
(https://twitter.com/UHhospitals). For more information, visit UHhospitals.org
(http://www.uhhospitals.org/).
Forward-Looking Statements
This press release contains "forward-looking statements". Forward-looking
statements reflect our current view about future events. When used in this press
release, the words "anticipate," "believe," "estimate," "expect," "future,"
"intend," "plan," or the negative of these terms and similar expressions, as
they relate to us or our management, identify forward-looking statements. Such
statements include, but are not limited to, statements contained in this press
release relating to our business strategy, our future operating results and
liquidity and capital resources outlook. Forward-looking statements are based on
our current expectations and assumptions regarding our business, the economy and
other future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Our actual results may differ
materially from those contemplated by the forward-looking statements. They are
neither statements of historical fact nor guarantees of assurance of future
performance. We caution you therefore against relying on any of these forward-
looking statements. Important factors that could cause actual results to differ
materially from those in the forward-looking statements include, without
limitation, our ability to raise capital to fund continuing operations; our
ability to protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us; competition from
other providers and products; our ability to develop and commercialize products
and services; changes in government regulation; our ability to complete capital
raising transactions; and other factors relating to our industry, our operations
and results of operations. Actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from
time to time, and it is not possible for us to predict all of them. We cannot
guarantee future results, levels of activity, performance or achievements.
AccuStem Sciences, Inc. assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may arise after
the date of this release.
Media Contact:
Jeff Fensterer
Email: jeff@accustem.com (mailto:jeff@accustem.com)
Investor Contact:
Wendy Blosser
Email: investors@accustem.com (mailto:investors@accustem.com)
Â

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH